The CEO of the nonprofit MassChallenge describes the way it supports startups and entrepreneurs, and why it has chosen Dallas as its second region of major focus in the U.S. outside of Boston
Biotech entrepreneur RA Session II describes converting science from UT Southwestern into companies - he currently has a new one that is in stealth mode
The CEO of LH Capital, a key supporter of the life sciences industry in North Texas, describes the progress the biotech community here has made over the last year
Southlake, TX based OncoNano Medicine is harnessing nanotechnology to identify and target cancer - a lead program hits the STING pathway
UT Southwestern professor Philipp Scherer talks about his work focusing on adipose cells and a local biotech company, PriveBio, that has come out of it
An investigator from MGH and the CSO of Inozyme discuss p1 data at Kidney Week showing that INZ-701 raised the levels of inorganic pyrophosphate, making it a possible treatment for calciphylaxis
Vera's CEO discusses the 96-week follow up results for Atacicept in IgAN that were presented this weekend at Kidney Week in San Diego
Kojin Therapeutics Chairman & CEO Harvey Berger shares an update on the company's progress and talks about the funding environment for earlier stage companies in biotech
Purespring Therapeutics raised a $105M series B earlier this month to advance AAV gene therapies for kidney diseases, including both monogenic and non-monogenic diseases
Transcriptional regulation in disease: opportunities, challenges, and the future
A father and patient advocate discuss Canavan disease and a daughter's experience on a gene therapy clinical trial
Piper Sandler analyst Biren Amin discusses recent news in ATTR cardiomyopathy, ophthalmology, Duchenne muscular dystrophy, and more
SecondWave Systems is using low intensity ultrasound to treat inflammatory conditions like RA
San Diego based Libra Therapeutics is aiming to boost protein clearance in neurodegenerative diseases by targeting TRPML1
Cambridge, MA based Lytica Therapeutics is trying to make antibody-drug conjugates more efficient by designing the antibody portion in a way that makes cells internalize them better
Since winning a pitch competition a year ago, Synthis Therapeutics has been working out of JLABS' Manhattan location on a TGF-β antibody drug conjugate
BioVenture VoiCes Episode 4: Enavate Sciences’ Sara Nayeem
Backed by a conglomerate that has pharma expertise, Rome based Angelini Ventures has a $300M fund that invests broadly in life sciences and healthcare
Entrepreneur Pierluigi Paracchi on San Raffaele, biotech in Italy, and his company Genenta Science
Milan based Enthera Pharmaceuticals is working in the autoimmune space with an asset that targets a unique pathway and that is the result of local research
.png){kind=logo}
